Ocugen Secures FDA Clearance for Novel Eye Therapy Candidate

A prolonged regulatory standoff with U.S. health authorities has concluded favorably for Ocugen. The biopharmaceutical company announced that the Food and Drug Administration has removed the clinical hold on its innovative ophthalmology treatment, OCU200. This decision enables the initiation of a Phase 1 clinical trial for the therapy, which targets diabetic macular edema.

The October 9, 2024 announcement represents a critical achievement for Ocugen’s development program. The FDA’s removal of the regulatory restriction now permits human testing of OCU200 to proceed through a multicenter dose-finding study.

OCU200 addresses a significant therapeutic gap affecting approximately 746,000 Americans living with diabetic macular edema, a vision-threatening condition that can progress to blindness. Current anti-VEGF treatments fail to produce adequate responses in... Read more...